{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:48:04Z","timestamp":1780372084707,"version":"3.54.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to clarify factors associated with polypharmacy among patients with systemic lupus erythematosus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-centre cross-sectional study was conducted by reviewing the medical records and questionnaire data of 261 systemic lupus erythematosus patients at a teaching hospital in Japan from 1 September to 30 November 2020. Polypharmacy was defined as the regular administration of five or more oral medications; excessive polypharmacy consisted of the regular use of 10 or more oral medications. This study investigated (1) the prevalence of polypharmacy and excessive polypharmacy, (2) the distribution of medication types, and (3) the factors associated with polypharmacy and excessive polypharmacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The proportions of patients who exhibited polypharmacy and excessive polypharmacy were 70% and 19%, respectively. Polypharmacy was associated with older age, long duration of systemic lupus erythematosus, high disease activity, and administration of glucocorticoids or immunosuppressive agents. Excessive polypharmacy was associated with a higher updated Charlson comorbidity index, history of visits to multiple internal medicine clinics, and presence of public assistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Polypharmacy and excessive polypharmacy in patients with systemic lupus erythematosus are related to medical aspects such as disease severity and comorbidities in addition to social aspects such as hospital visitation patterns and economic status.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac155","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T17:41:19Z","timestamp":1670866879000},"page":"106-112","source":"Crossref","is-referenced-by-count":9,"title":["Polypharmacy prevalence and associated factors in patients with systemic lupus erythematosus: A single-centre, cross-sectional study"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-6356","authenticated-orcid":false,"given":"Hirofumi","family":"Miyake","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi Minoda","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara, Japan"},{"name":"Department of Infection Control, Graduate School of Medicine, Osaka University , Osaka, Japan"},{"name":"Department of Transformative Protection to Infectious Disease, Graduate School of Medicine, Osaka University , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akebo","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Tsugihashi","sequence":"additional","affiliation":[{"name":"Medical Home Care Centre, Tenri Hospital Shirakawa Branch , Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Hatta","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"2024061306563627000_R1","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"2024061306563627000_R2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/pds.1984","article-title":"Adverse drug events in the outpatient setting: an 11-year national analysis","volume":"19","author":"Bourgeois","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024061306563627000_R3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/0971-6580.94506","article-title":"A survey on polypharmacy and use of inappropriate medications","volume":"19","author":"Rambhade","year":"2012","journal-title":"Toxicol Int"},{"key":"2024061306563627000_R4","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/acr.23191","article-title":"Medication nonadherence in systemic lupus erythematosus: a systematic review","volume":"69","author":"Mehat","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024061306563627000_R5","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/0961203312447868","article-title":"Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring","volume":"21","author":"Marengo","year":"2012","journal-title":"Lupus"},{"key":"2024061306563627000_R6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/kez037","article-title":"Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563627000_R7","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3899\/jrheum.160818","article-title":"Polypharmacy and unplanned hospitalizations in patients with rheumatoid arthritis","volume":"44","author":"Filkova","year":"2017","journal-title":"J Rheumatol"},{"key":"2024061306563627000_R8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/rheumatology\/kex469","article-title":"Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register","volume":"57","author":"Subesinghe","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2024061306563627000_R9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/mr\/roab130","article-title":"Clinical observations of osteoporosis in Japanese patients with rheumatoid arthritis","volume":"32","author":"Furuya","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024061306563627000_R10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/RHU.0000000000000463","article-title":"Disease activity score on 28 joints and polypharmacy are independent predictors for health-related quality of life evaluated by INCAVISA in patients with rheumatoid arthritis","volume":"22","author":"Gonz\u00e1lez-Gamboa","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"2024061306563627000_R11","article-title":"Polypharmacy and potentially inappropriate medication use in older adults with systemic lupus erythematosus","author":"S\u00e9guin","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024061306563627000_R12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2024061306563627000_R13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"2024061306563627000_R14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"2024061306563627000_R15","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2024061306563627000_R16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024061306563627000_R17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165910","article-title":"Recognizing novel chemicals\/drugs for anatomical therapeutic chemical classes with a heat diffusion algorithm","volume":"1866","author":"Liang","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2024061306563627000_R18","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"2024061306563627000_R19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2024061306563627000_R20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2020.11.066","article-title":"Disproportionately low BNP levels in patients of acute heart failure with preserved vs. reduced ejection fraction","volume":"327","author":"Sakane","year":"2021","journal-title":"Int J Cardiol"},{"key":"2024061306563627000_R21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10157-018-1648-1","article-title":"Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018","volume":"23","author":"Japanese Society of Nephrology","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"2024061306563627000_R22","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/jgs.15569","article-title":"Trends in polypharmacy in Japan: a nationwide retrospective study","volume":"66","author":"Onoue","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"2024061306563627000_R23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/ggi.12591","article-title":"Association between polypharmacy and multiple uses of medical facilities in nursing home residents","volume":"16","author":"Kojima","year":"2016","journal-title":"Geriatr Gerontol Int"},{"key":"2024061306563627000_R24","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/193168","article-title":"Chronic condition clusters and polypharmacy among adults","volume":"2012","author":"Vyas","year":"2012","journal-title":"Int J Family Med"},{"key":"2024061306563627000_R25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/pop.2017.0065","article-title":"Polypharmacy and multimorbidity among Medicaid enrollees: a multistate analysis","volume":"21","author":"Feng","year":"2018","journal-title":"Popul Health Manag"},{"key":"2024061306563627000_R26","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in older adults hospitalized for heart failure","volume":"13","author":"Unlu","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2024061306563627000_R27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11897-014-0186-8","article-title":"Polypharmacy in heart failure patients","volume":"11","author":"Mastromarino","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"2024061306563627000_R28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","article-title":"Polypharmacy definition and prevalence in heart failure: a systematic review","volume":"27","author":"Beezer","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2024061306563627000_R29","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2024061306563627000_R30","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2215\/CJN.03940321","article-title":"Association of polypharmacy with kidney disease progression in adults with CKD","volume":"16","author":"Kimura","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024061306563627000_R31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/ggi.12789","article-title":"Risk factors and consequences of decreased kidney function in nursing home residents: a longitudinal study","volume":"17","author":"Bolmsj\u00f6","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"2024061306563627000_R32","article-title":"Risk of kidney dysfunction from polypharmacy among older patients: a nested case-control study of the South Korean senior cohort","volume":"9","author":"Kang","year":"2019","journal-title":"Sci Rep"},{"key":"2024061306563627000_R33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jamda.2019.07.007","article-title":"Polypharmacy and kidney function in community-dwelling adults age 60 years and older: a prospective observational study","volume":"21","author":"Ernst","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"2024061306563627000_R34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40266-018-0563-1","article-title":"Kidney function, polypharmacy, and potentially inappropriate medication use in a community-based cohort of older adults","volume":"35","author":"Secora","year":"2018","journal-title":"Drugs Aging"},{"key":"2024061306563627000_R35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1370\/afm.778","article-title":"The inverse care law: clinical primary care encounters in deprived and affluent areas of Scotland","volume":"5","author":"Mercer","year":"2007","journal-title":"Ann Fam Med"},{"key":"2024061306563627000_R36","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-12-201","article-title":"Multimorbidity prevalence and patterns across socioeconomic determinants: a cross-sectional survey","volume":"12","author":"Agborsangaya","year":"2012","journal-title":"BMC Public Health"},{"key":"2024061306563627000_R37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/jdi.13435","article-title":"Non-financial social determinants of diabetes among public assistance recipients in Japan: a cohort study","volume":"12","author":"Nishioka","year":"2021","journal-title":"J Diabetes Investig"},{"key":"2024061306563627000_R38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1467-842X.2003.tb00424.x","article-title":"The prevalence of mental disorders among income support recipients: an important issue for welfare reform","volume":"27","author":"Butterworth","year":"2003","journal-title":"Aust N Z J Public Health"},{"key":"2024061306563627000_R39","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/jech-2021-217296","article-title":"Medical expenditure after marginal cut of cash benefit among public assistance recipients in Japan: natural experimental evidence","volume":"76","author":"Nishioka","year":"2021","journal-title":"J Epidemiol Community Health"},{"key":"2024061306563627000_R40","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-018-6337-1","article-title":"The impact of social assistance programs on population health: a systematic review of research in high-income countries","volume":"19","author":"Shahidi","year":"2019","journal-title":"BMC Public Health"},{"key":"2024061306563627000_R41","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2024061306563627000_R42","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/aje\/kws130","article-title":"Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus","volume":"176","author":"Magder","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2024061306563627000_R43","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3904\/kjim.2018.303","article-title":"Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study","volume":"35","author":"Bae","year":"2020","journal-title":"Korean J Intern Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac155\/54151994\/roac155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/1\/106\/58214117\/roac155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/1\/106\/58214117\/roac155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T10:24:11Z","timestamp":1718274251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/1\/106\/6889189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,12]]},"published-print":{"date-parts":[[2023,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac155","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2022,12,12]]}}}